Home / CDMO CDMO API Contract Development and manufacturing opportunities Pharma companies need new and more complex API developments every day. This involves longer and more complicated R&D and regulation processes. If you are facing new challenges, we can provide solutions. Our research expertise allow us to accept API CDMO (Contract Development and Manufacturing Organization) requests, in addition to our existing product catalogue. Lebsa’s experience and ﬂexibility allows us to manufacture from a laboratory scale of just a few grams to some kilograms in our GMP pilot plant (10, 63 and 250 litres reactors) or to industrial quantities (1600 or 2500 litres reactors). Compliance with the highest cGMP standards is always assured. VIEW GMP PILOT PLANT Our highly trained technical team is ready to work closely with you at every stage, offering total confidentiality, rapid responses and full regulatory support. More about Lebsa Beyond Quality Regulatory Support Sustainability Customer Support LEBSA, your partner in API’s Manufacturing in Barcelona (EU) US Your Partner in API’s Manufacturing Who we are Legal Notice Standard API’s API’s Pipeline Customer Support API R&D Contact Info 2021 LEBSA All rights reserved. Website Powered by tbbAgency By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. Cookies Settings Reject All Accept All Cookies

Home / APIs / Amisulpride Amisulpride Main Therapeutic Application: Antipsychotics agent/ Neuroleptic agent CAS-RN: 71675-85-9 CONTACT US More information Amisulpride (CAS-RN 71675-85-9) is an antipsychotic used to treat schizophrenia and also dysthymia. Amisulpride works by reducing signaling, blocking the D2 receptor. By obstructing the receptors that regulate the release of dopamine into the synapse, amisulpride increases the dopamine concentration in this process. The increased dopamine concentration acts on another dopamine receptor and relieves depressive and the negative symptoms of schizophrenia. Product information Amisulpride Main Therapeutic Application: Antipsychotics agent/ Neuroleptic agent CAS-RN: 71675-85-9 Specification: Ph. Eur. Documentation: EDMF/CEP Related Products Tiapride Hydrochloride Main Therapeutic Application: Antipsychotic agent/ Neuroleptic agent CAS-RN: 51012-33-0 More information Sulpiride Main Therapeutic Application: Antipsychotic agent/ Neuroleptic agent CAS-RN: 15676-16-1 More information LEBSA, your partner in API’s Manufacturing in Barcelona (EU) US Your Partner in API’s Manufacturing Who we are Legal Notice Standard API’s API’s Pipeline Customer Support API R&D Contact Info 2021 LEBSA All rights reserved. Website Powered by tbbAgency By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. Cookies Settings Reject All Accept All Cookies